Emphysema Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.54 Billion
CAGR (2026-2031)	6.14%
Fastest Growing Segment	Ambulatory Surgical Centers
Largest Market	North America
Market Size (2031)	USD 6.49 Billion

Market Overview

The Global Emphysema Treatment Market will grow from USD 4.54 Billion in 2025 to USD 6.49 Billion by 2031 at a 6.14% CAGR. Emphysema treatment encompasses a range of therapeutic interventions, including pharmacotherapies such as bronchodilators and corticosteroids, as well as lung volume reduction procedures, designed to manage alveolar destruction and improve respiratory function. The market is primarily driven by the escalating global prevalence of tobacco smoking and persistent exposure to environmental pollutants, alongside an expanding geriatric population that is increasingly susceptible to progressive respiratory degradation. These factors collectively sustain a growing demand for effective management strategies distinct from emerging technological trends in drug delivery.

However, the market faces significant impediments due to the high cost of advanced therapies and stringent regulatory requirements that often delay the commercialization of novel treatments. According to the COPD Foundation, in 2025, it was estimated that chronic obstructive pulmonary disease affects more than 30 million individuals in the United States, underscoring the substantial yet often underdiagnosed patient burden that necessitates accessible therapeutic solutions.

Key Market Drivers

The development of novel biologics and triple-combination therapies is fundamentally reshaping the market by addressing specific inflammatory pathways that were previously unmanaged by standard bronchodilators. Recent regulatory approvals have introduced mechanisms targeting phosphodiesterase inhibitors and type 2 inflammation, offering transformative benefits for patients with moderate to severe phenotypes who suffer from frequent exacerbations. This therapeutic shift is evidenced by rapid commercial uptake; according to Verona Pharma, April 2025, in the 'First Quarter 2025 Financial Results', the company reported net product sales of $71.3 million for its newly launched maintenance therapy, Ohtuvayre. These advancements are particularly urgent as persistent exposure to environmental pollutants continues to widen the patient pool necessitating advanced care. According to the American Lung Association, in 2025, 156 million people in the United States lived in counties with unhealthy air quality, thereby sustaining the high demand for effective respiratory interventions.

Simultaneously, the adoption of minimally invasive lung volume reduction (LVR) procedures acts as a critical driver for treating severe emphysema where pharmacological management alone proves insufficient. Endobronchial valves are increasingly preferred over invasive surgical options due to their reduced recovery times and ability to effectively occlude diseased lung lobes to improve breathing mechanics. This segment is witnessing robust expansion as healthcare systems globally align with updated treatment guidelines favoring these interventional devices. For instance, according to Pulmonx Corporation, November 2025, in the 'Third Quarter 2025 Financial Results', the company achieved worldwide revenue of $21.5 million, reflecting the expanding global utilization of its Zephyr Valve system for severe emphysema management.

Download Free Sample Report

Key Market Challenges

The high cost of advanced therapies and stringent regulatory requirements constitute a primary impediment to the Global Emphysema Treatment Market. These economic and procedural barriers directly hamper market growth by restricting patient access to necessary interventions and delaying the commercialization of new products. Advanced pharmacotherapies and lung volume reduction procedures often carry premium pricing, placing a substantial financial burden on healthcare systems and uninsured individuals. Consequently, adoption rates in price-sensitive regions remain low, limiting the potential revenue expansion for manufacturers. Furthermore, rigorous regulatory frameworks necessitate extensive capital investment and prolonged clinical trial phases, which increases the financial risk for companies attempting to introduce novel therapeutics.

This economic strain is further evidenced by the broader financial impact of respiratory conditions on productivity. According to a joint report by the World Health Organization and the European Respiratory Society published in 2025, the regional productivity loss attributable to chronic respiratory diseases was estimated at US$20.7 billion. This figure highlights the severe economic consequences of limited treatment accessibility. As high costs and regulatory delays persist, they create a bottleneck that prevents the market from fully capitalizing on the rising demand, effectively stalling growth despite the increasing prevalence of the disease.

Key Market Trends

The rise of robotic-assisted interventional bronchoscopy systems is significantly altering the procedural landscape for emphysema by enabling precise access to peripheral lung regions previously unreachable by conventional methods. These robotic platforms utilize shape-sensing technology and ultra-thin catheters to provide stability and reach distal airways, allowing pulmonologists to perform biopsies or deliver treatments with greater accuracy and safety. This capability is particularly vital for emphysema patients with compromised lung architecture, as it minimizes the risk of pneumothorax associated with percutaneous needle approaches and facilitates earlier intervention in complex cases. The market's strong shift toward these automated navigational tools is evidenced by rapid adoption rates in clinical settings. According to Intuitive Surgical, April 2025, in the 'First Quarter 2025 Financial Results', the company reported that Ion procedures grew 58% compared to the first quarter of the previous year, signaling a major expansion in the utilization of robotic-assisted respiratory interventions.

Simultaneously, the implementation of remote digital respiratory monitoring solutions is transforming long-term disease management by shifting the focus from reactive acute care to continuous, data-driven home support. These digital ecosystems integrate cloud-connected therapeutic devices that track critical metrics such as airflow, adherence, and leak rates, transmitting real-time data to healthcare providers to preempt exacerbations. This connectivity reduces the frequency of hospital readmissions and optimizes resource allocation by allowing clinicians to adjust care plans without requiring physical office visits. The commercial traction of this digital health model is substantiated by the growing revenue streams of leading medical device manufacturers. According to ResMed Inc., August 2025, in the 'Form 10-K for the Fiscal Year Ended June 30, 2025', the Residential Care Software segment generated revenue of $641.4 million, representing a 10% increase over the prior fiscal year, validating the increasing reliance on connected software solutions for respiratory health management.

Segmental Insights

The Ambulatory Surgical Centers segment is emerging as the fastest-growing category in the Global Emphysema Treatment Market. This rapid expansion is primarily driven by the increasing adoption of minimally invasive interventional pulmonology techniques, such as bronchoscopic lung volume reduction, which are gradually replacing complex invasive surgeries. These procedures align with the operational efficiency of ambulatory centers, offering patients reduced recovery times and a lower risk of hospital-acquired infections. Furthermore, favorable reimbursement policies from regulatory bodies like the Centers for Medicare & Medicaid Services have expanded the scope of approved outpatient respiratory procedures, incentivizing the shift toward these cost-effective treatment settings.

Regional Insights

North America leads the Global Emphysema Treatment Market due to the high prevalence of chronic respiratory conditions and a well-established healthcare infrastructure. The region benefits significantly from proactive initiatives by the US Food and Drug Administration, which facilitates the approval of essential medical devices and pharmaceutical therapies. Furthermore, widespread availability of reimbursement programs encourages higher patient diagnosis and treatment rates across the United States and Canada. This robust regulatory environment, coupled with the strong presence of key industry manufacturers, ensures consistent market expansion and accessibility for patients throughout the region.

Recent Developments

• In January 2025, Mereo BioPharma reported significant regulatory progress for alvelestat, its oral neutrophil elastase inhibitor designed to treat Alpha-1 Antitrypsin Deficiency-associated lung disease. The company announced that the Committee for Orphan Medicinal Products of the European Medicines Agency had issued a positive opinion regarding the application for Orphan Designation for the drug. This development is a critical step for the investigational therapy, which aims to protect lung tissue from enzymatic damage that leads to emphysema. The company also confirmed it was finalizing the design of a global Phase 3 study to support future marketing applications in the United States and Europe.
• In September 2024, Pulmonx Corporation presented positive long-term data regarding its minimally invasive treatment for severe emphysema at the European Respiratory Society International Congress. The five-year results from the LIBERATE study demonstrated that patients treated with the Zephyr Endobronchial Valve achieved sustained improvements in lung function and exercised capacity compared to those receiving medical management alone. Furthermore, the data indicated a survival benefit for the treatment group over the five-year period. These findings reinforced the durability and long-term efficacy of bronchoscopic lung volume reduction as a standard of care for patients with hyperinflated lungs caused by advanced emphysema.
• In June 2024, Verona Pharma secured approval from the U.S. Food and Drug Administration for Ohtuvayre (ensifentrine) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). This launch represented the first inhaled therapy with a new mechanism of action to enter the market in more than twenty years. The drug operates as a selective dual inhibitor of the phosphodiesterase 3 and 4 enzymes, delivering both bronchodilation and non-steroidal anti-inflammatory benefits via a standard jet nebulizer. This dual approach offers a new therapeutic option for patients, including those with emphysema, who suffer from persistent symptoms despite existing standard-of-care regimens.
• In May 2024, Sanofi announced the completion of its acquisition of Inhibrx, Inc., a strategic transaction valued at approximately $1.7 billion that expanded its rare disease portfolio. Through this agreement, the company obtained full rights to SAR447537 (formerly INBRX-101), a human recombinant protein currently in development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). This genetic condition significantly increases the risk of developing pulmonary emphysema due to a lack of protective proteins in the lungs. The acquisition underscored the company's commitment to advancing novel therapies that address the underlying causes of progressive lung tissue destruction in patients with this deficiency.

Key Market Players

• Icure Pharmaceuticals Inc.
• AstraZeneca Plc.
• Teva Pharmaceuticals Industries Ltd.
• Novartis AG
• GlaxoSmithKline Plc.
• Hikma Pharmaceuticals Plc
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Pfizer Inc.
• Orion Corporation

By Treatment	By Distribution Channel	By End-User	By Region
Smoking Cessation Bronchodilators Steroids Leukotriene Modifiers Supplemental Oxygen Antibiotics Gene Therapy Surgery Transplant Other Treatments	Hospital Pharmacy Retail Pharmacy Other Distribution Channels	Hospitals & Clinics Ambulatory Surgical Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Emphysema Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Emphysema Treatment Market, By Treatment:

• Smoking Cessation
• Bronchodilators
• Steroids
• Leukotriene Modifiers
• Supplemental Oxygen
• Antibiotics
• Gene Therapy
• Surgery Transplant
• Other Treatments

• Emphysema Treatment Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels

• Emphysema Treatment Market, By End-User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

• Emphysema Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE